SanGene NIPT Genome Screen
SanGene NIPT Genome Screen is a non-invasive prenatal test that analyses the baby’s cell-free DNA in the mother’s blood by whole-genome sequencing, from 10 weeks of pregnancy. It assesses the risk of trisomies 21, 18 and 13, sex chromosome conditions, rare aneuploidies of the other chromosomes and deletions and duplications larger than 7 Mb, and determines the baby’s sex.
Preparation and sampling
- Preparation
- Guide to preparing for tests
- Sample
- Blood
- Results available in
- 10 working days
- Where it is done
- All laboratories and map
Description
About the test
SanGene NIPT Genome Screen is a non-invasive prenatal test: it is done on an ordinary venous blood sample from the mother, so it carries no risk for either mother or baby. It analyses the cell-free DNA circulating in the mother’s blood, part of which comes from the placenta, and from as early as 10 weeks of pregnancy it provides important information for further pregnancy care.
The test uses next-generation whole-genome sequencing (NGS, paired-end): instead of examining only selected chromosomes, it ‘reads’ cell-free DNA fragments from all chromosomes. From one blood sample it can therefore assess, in addition to the most common trisomies and sex chromosome conditions, rare aneuploidies of the other chromosomes and large deletions and duplications. Paired-end sequencing allows the baby’s DNA to be distinguished from the mother’s, which improves the estimate of the proportion of the baby’s DNA in the sample (the fetal fraction) and the reliability of the test. According to the manufacturer’s data, the sensitivity and specificity of the test for the common trisomies are over 99%, which reduces the number of false-positive results and unnecessary invasive procedures.
The test assesses the risk of the following conditions in the baby:
- Trisomy 21 (Down’s syndrome) – learning disability of varying degree, characteristic facial features, low muscle tone in the newborn and frequent heart defects; there is also an increased risk of leukaemia and early-onset Alzheimer’s disease.
- Trisomy 18 (Edwards’ syndrome) – severe learning disability, growth restriction already in the womb, a small head, low-set ears and a small lower jaw, a characteristic hand position (clenched fists with overlapping fingers), heart and kidney defects; life expectancy is very limited.
- Trisomy 13 (Patau’s syndrome) – severe learning disability, a small head and severe brain malformations, cleft lip and palate, extra fingers or toes, heart and kidney defects; most affected babies do not survive their first year.
- Turner syndrome (45,X) – short stature, a webbed neck, a low hairline, underdeveloped ovaries and infertility, heart defects (for example narrowing of the aorta); intelligence is usually normal.
- Klinefelter syndrome (47,XXY) – taller stature, breast enlargement, small testes and infertility, reduced testosterone production, sometimes mild learning difficulties.
- Triple X syndrome (47,XXX) – usually without symptoms; sometimes somewhat taller stature and learning and speech difficulties; fertility is usually normal.
- Jacobs syndrome (47,XYY) – taller stature, severe acne in adolescence, sometimes behavioural difficulties and impulsiveness; intelligence is normal or slightly reduced, and fertility is usually normal.
- Rare autosomal aneuploidies (RAA) – an extra or missing copy of a chromosome other than 13, 18 or 21, for example trisomy 8, 9, 16 or 22. In their complete form they are as a rule not compatible with life and are common in miscarriages; in a mosaic form, when only some cells are affected, they can be linked to growth restriction in the womb, premature birth, birth defects and developmental delay.
- Deletions and duplications larger than 7 Mb (CNVs) – a missing or extra larger part of a chromosome; the effects depend on the region involved, most often developmental delay, changes to the face and head and birth defects of organs.
- Baby’s sex – determined from the presence of the Y chromosome in the baby’s cell-free DNA.
Among the rare aneuploidies, trisomy 16 is the most common trisomy in miscarriages, while trisomies 8, 9 and 22 occur in liveborn children almost only in a mosaic form, with more severe disorders of growth and development.
When it is recommended
International professional bodies, such as the American College of Obstetricians and Gynecologists (ACOG), recommend that all pregnant women be informed about the option of non-invasive prenatal testing for the most common chromosomal conditions. The test is recommended:
- for pregnant women of all ages, especially those over 35;
- in singleton pregnancies;
- for couples with genetic conditions in the family;
- for women with abnormal results on other prenatal screening tests (for example the double or triple test) or on a fetal ultrasound scan;
- in pregnancies after IVF, including pregnancies with a donor egg and surrogate pregnancies.
The test is intended for singleton pregnancies; a separate version of the test is available for twin pregnancies.
Preparation
- The test can be done from 10 weeks of pregnancy; the length of the pregnancy should be confirmed by ultrasound.
- Sampling is by appointment: contact the laboratory to find out when and where you can give the sample.
- You do not need to fast, and the sample can be given at any time of day.
- If you have had a blood transfusion, at least 4 weeks, and ideally 8 weeks, should pass between the transfusion and sampling. Also say if you have had an organ or bone marrow transplant.
- At sampling, give the details of the pregnancy: its length, the number of babies and whether it was achieved by IVF, with a donor egg or as a surrogate pregnancy. Bring your ultrasound report and your doctor’s referral, if you have one.
- Before the test, it is advisable to discuss with your gynaecologist or a geneticist what the test can and cannot detect.
Sample
Venous blood from the mother: one 10 ml tube of a special type (Streck), which preserves the cell-free DNA until analysis.
Interpreting the results
- Low risk – it is very unlikely that the baby has any of the conditions examined. However, the test does not detect all genetic conditions (for example smaller deletions and duplications, single-gene disorders or structural defects), so regular ultrasound scans remain essential.
- High risk – the test is a screening test, not a diagnosis. A positive result should be confirmed by a diagnostic test on amniotic fluid (amniocentesis) or chorionic villi, together with a discussion with a geneticist and a gynaecologist. Decisions about the pregnancy are not made on the basis of this test alone.
- Rare aneuploidies and large deletions or duplications – genetic counselling and diagnostic confirmation are particularly important for interpreting such a finding.
- No result – sometimes no result can be issued; a repeat sample may then be needed.
Your doctor interprets the result together with your symptoms and other findings.
What can affect the result
- too low a proportion of the baby’s DNA in the mother’s blood (the fetal fraction), which sometimes means no result can be issued;
- an incorrectly estimated length of pregnancy; the test is not done before 10 weeks;
- a blood transfusion in the previous 4 to 8 weeks or an organ or bone marrow transplant, as another person’s DNA can affect the result;
- chromosome changes confined to the placenta (so-called confined placental mosaicism): the baby’s cell-free DNA comes from the placenta, so a finding, especially of rare aneuploidies and large deletions or duplications, sometimes does not reflect the baby’s condition;
- a baby that stopped developing early in the pregnancy (a so-called vanishing twin): its DNA can remain in the mother’s blood for some time and affect the result.
Related tests
- carrier screening of the parents for recessive genetic conditions (expanded gene panels);
- carrier testing for the CFTR F508del (cystic fibrosis) and GJB2 35delG (hereditary deafness) mutations;
- the double test (first-trimester combined screening);
- first-trimester pre-eclampsia risk assessment (PAPP-A and PlGF, from 11 weeks to 13 weeks and 6 days);
- a fetal anomaly ultrasound scan;
- amniocentesis or chorionic villus sampling to confirm a raised risk, with genetic counselling.
Frequently ordered together
How to order tests online?
Choose the tests you need and add them to your cart. Use the site search to find the tests you want more easily.
Payment method:
- Online – payment uses 3D-Secure, a secure authentication protocol that minimises the risk of fraud.
- At the laboratory – order your tests online and pay for them when you come to the laboratory.
After payment, you will receive an email confirming your order, with details of how to prepare for sampling. From then on, you can go to the Sante laboratory you chose when ordering your tests and have your samples taken.